Related Experiment Video
Updated: May 22, 2025
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
NSD2 and miRNAs as Key Regulators of Melanoma Response to Romidepsin and Interferon-α2b Treatment
Alessandro De Santis1, Lucrezia De Santis1, Francesca Rossi2
1Department of Biology and Biotechnology Charles Darwin, Sapienza University of Rome, Rome, Italy.
Background:
We investigated the role of Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and microRNAs (miRNAs) in melanoma de-differentiation following Romidepsin and Interferon-α2b (RI) treatment. Melanoma is the most lethal form of skin cancer, and despite advancements in therapy, treatment resistance remains a major challenge. De-differentiation has been widely recognized as a key factor contributing to therapy resistance.
Methods:
RNA-seq and TCGA transcriptomic data were re-analyzed to identify miRNAs and NSD2 expressions. The functional impact of selected miRNAs was then investigated at the molecular and phenotypic levels using primary and immortalized cell lines.
Results:
Our findings demonstrate that RI treatment induces a de-differentiation process in primary melanoma cells, resembling that observed in therapy-resistant melanoma. This effect is particularly pronounced in cells with an intrinsic proliferative phenotype, where we observed significant downregulation of NSD2, a key epigenetic regulator implicated in multiple cancers. Additionally, we identified specific miRNAs as mediators of NSD2 downregulation, influencing melanoma cell viability and fitness.
Conclusions:
These findings provide new insights into the molecular mechanisms driving melanoma progression and highlight potential therapeutic targets to counteract treatment resistance.
Insights
Romidepsin and Interferon-α2b (RI) treatment induced melanoma cell de-differentiation and therapy resistance. This process involves microRNAs (miRNAs) and downregulation of the epigenetic regulator Nuclear Receptor Binding SET Domain Protein 2 (NSD2).
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Melanoma poses a significant challenge due to therapy resistance.
- Cellular de-differentiation is a key mechanism underlying treatment resistance in melanoma.
- Understanding the molecular drivers of de-differentiation is crucial for developing effective therapies.
Purpose of the Study:
- To investigate the roles of Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and microRNAs (miRNAs) in melanoma de-differentiation after Romidepsin and Interferon-α2b (RI) treatment.
- To identify molecular mechanisms contributing to therapy resistance in melanoma.
Main Methods:
- Re-analysis of RNA-sequencing and TCGA transcriptomic data to assess miRNA and NSD2 expression.
- Functional investigation of selected miRNAs in primary and immortalized melanoma cell lines.
- Molecular and phenotypic analyses to determine the impact of miRNA and NSD2 alterations.
Main Results:
- RI treatment induced melanoma cell de-differentiation, mimicking therapy-resistant phenotypes.
- Significant downregulation of NSD2, an epigenetic regulator, was observed in proliferative melanoma cells.
- Specific miRNAs were identified as mediators of NSD2 downregulation, affecting melanoma cell viability and fitness.
Conclusions:
- RI treatment triggers melanoma de-differentiation via miRNA-mediated NSD2 downregulation.
- These findings offer novel insights into melanoma progression and therapeutic resistance.
- Targeting NSD2 or associated miRNAs could be a strategy to overcome treatment resistance in melanoma.
Related Concept Videos
01:22MicroRNAs
02:23Abnormal Proliferation